New database to track neurological symptoms of COVID-19
NeuroCOVID will be a resource of clinical information and biospecimens from people who experience neurological problems associated with SARS-CoV-2 infection.
List view / Grid view
NeuroCOVID will be a resource of clinical information and biospecimens from people who experience neurological problems associated with SARS-CoV-2 infection.
A study has shown that patients with severe COVID-19 have significantly elevated levels of M-MDSCs in their blood compared with healthy individuals.
Learn how Simple Western automated immunoassays screen degraders and IMiD compounds to quantify degradation activity, providing accurate DC50 and Dmax values.
A single vaccination with a mutated Leptospira bacteria prevented rodent models from developing leptospirosis, the most fatal type of zoonotic disease worldwide.
The lead candidate, ADG2, was able to neutralise SARS-CoV and various strains of SARS-CoV-2, including those that are resistant to currently available antibody treatments.
In murine models of COVID-19, researchers found that non-steroidal anti-inflammatory drugs (NSAIDs) can suppress the inflammatory response and production of antibodies.
A study has shown that the immune response of rhesus macaques with SARS-CoV-2 could be reproduced with a vaccine.
Researchers suggest patients who develop mild COVID-19 may not be able to fight reinfection very effectively because their CD8+ T cells show signs of exhaustion.
The discovery of an inflammatory pathway promoting brain ageing and cognitive decline could lead to new treatments for age-related conditions.
This tissue-specific handbook brings you key publications, in-house protocols and troubleshooting recommendations for your organoid cell culture.
Using synthetic chemistry, researchers have fused hydrophobic adjuvants with water-soluble proteins to create a new type of vaccine.
According to a Public Health England study, prior SARS-CoV-2 infection provides 83 percent protection against reinfection but may not stop individuals spreading COVID-19.
By combining nanobodies targeting different regions of the SARS-CoV-2 Spike protein, researchers were able to protect cells from infection.
A new protein-based nanoparticle vaccine protected mice against a variety of coronaviruses, researchers have shown.
A team has found immune cells in the lungs after infection from the flu, which protected mice against reinfection from a different strain.